Our unique process, paired withinnovation and continued improvement and evolution, puts us at the forefront.
Humacyte Appoints Doug Blankenship as Chief Financial Officer
U.S. Kidney Patients Help Drive Care Innovation Patient insights Accelerate Research and Development
Bioengineered Blood Vessel Aims to Revolutionize Dialysis Access
Humacyte Appoints Jeffrey Lawson MD, PhD as President and Chief Executive Officer
From lower costs to fewer operations, HAVs may offer critical benefits.
With each year, we’ve movedcloser to lifesaving treatments.